BAVARIAN NORDIC
- Country
- 🇩🇰Denmark
- Ownership
- -
- Established
- 1992-01-01
- Employees
- 759
- Market Cap
- $3.1B
Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects
- Conditions
- HIV Infections
- Interventions
- Biological: MVA-mBN120B
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2010-05-20
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 15
- Registration Number
- NCT00623259
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 9
- Registration Number
- NCT00485277
- Locations
- 🇺🇸
Alta Bates Herrick Hospital Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection
- Conditions
- HIV Infections
- Interventions
- Biological: MVA-mBN32Biological: IMVAMUNE
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 30
- Registration Number
- NCT00390078
- Locations
- 🇩🇪
Charité, Campus Virchow-Klinikum, Berlin, Germany
Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection
- Conditions
- HIV Infections
- Interventions
- Biological: MVA-mBN32
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 36
- Registration Number
- NCT00386633
- Locations
- 🇩🇪
LMU-Munich, Department of Infectious Diseases and Tropical Medicine, Munich, Germany
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Biological: IMVAMUNE
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 632
- Registration Number
- NCT00316602
- Locations
- 🇺🇸
Adult & Pediatric Dermatology PC, Overland Park, Kansas, United States
🇺🇸Alta Clinical Research LLC, Tucson, Arizona, United States
🇺🇸Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients
- Conditions
- HIV Infections
- Interventions
- Biological: IMVAMUNE (MVA-BN)
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 581
- Registration Number
- NCT00316589
- Locations
- 🇺🇸
AltaMed Health Services, Los Angeles, California, United States
🇺🇸The CORE Center, Chicago, Illinois, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects
- Conditions
- Smallpox
- Interventions
- Biological: PlaceboBiological: MVA-BN® (IMVAMUNE)
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 745
- Registration Number
- NCT00316524
- Locations
- 🇩🇪
Harrison Clinical Research GmbH, Munich, Bavaria, Germany
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders
- Conditions
- Dermatitis, AtopicHay Fever
- Interventions
- Biological: IMVAMUNE (MVA-BN)
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 60
- Registration Number
- NCT00189917
- Locations
- 🇩🇪
Department of Infectious Diseases and Tropical Medicine, Munich, Bavaria, Germany
An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients
- Conditions
- HIV Infection
- Interventions
- Biological: MVA-nefBiological: IMVAMUNE
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-10-01
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 77
- Registration Number
- NCT00189930
- Locations
- 🇩🇪
University of Erlangen, Erlangen, Bavaria, Germany
🇩🇪Doctor's Practice, Nürnberg, Bavaria, Germany
Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects
- Conditions
- Smallpox
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-04-21
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 50
- Registration Number
- NCT00189969
- Locations
- 🇩🇪
Focus Clinical Drug Development GmbH, Neuss, Nordrhein, Germany